secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0001493152-23-003646
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran receives CDSCO approval for first-in-human ProLectin-I trial
----------------------------------------------------------------------

- India's CDSCO granted IND authorization (CT-06, No. CT/ND/03/2023) to evaluate ProLectin-I injection.
- Trial will assess safety, tolerability, PK/PD; results to guide Phase II in Long COVID and IPF.
- Separate approval from prior ProLectin-M authorization (Dec 2, 2022).
- ProLectin-I targets viral persistence and fibrosis; Long COVID affects 65-100 million worldwide.
- Trial at each site requires ethics committee approval before initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315223003646/0001493152-23-003646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315223003646/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-003646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer